Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Bristol-Myers marches on in European melanoma care
Company: Bristol-Myers Squibb (BMY)
Therapy: Nivolumab
Disease: Melanoma
News: BMY announced that the EMA has approved its PD-1 inhibitor nivolumab in the setting of adjuvant therapy for melanoma after a complete resection. Patients can receive this treatment regardless of their BRAF mutational status. The approval was based on findings from the CheckMate-238 study, which demonstrated a significant improvement for